Eli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for RET inhibitor selpercatinib setting up a filing before the end of the year. The results of the ...
In BRUIN, LOXO-305 was tested in various types of NHL, including 61 patients with mantle cell lymphoma (MCL) and 19 with Waldenström's macroglobulinemia (WM) who had previously been treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback